All I want is an end to Novel Psychoactive Substances (NPS).
It’s a wish many of us in the forensic community share. NPS are the perennial “moving targets” of toxicology and drug chemistry, presenting an ongoing challenge to laboratory protocols and public safety. This week, we are diving into the messy world of synthetic benzodiazepines, specifically clonazolam and its potent metabolite, 8-aminoclonazolam.
The Physiological Signature: Nystagmus and CNS Depression
In recent case consultations involving significant impairment, a recurring physiological pattern has emerged. Subjects frequently exhibit both Horizontal Gaze Nystagmus (HGN) and Vertical Gaze Nystagmus (VGN).
While HGN is a common indicator of CNS depressant use, the presence of VGN is particularly telling. In the context of benzodiazepines, VGN typically indicates that the drug concentration is remarkably high for that specific individual. While users may develop a “behavioral tolerance” to certain cognitive effects, the eyes remain a window to physiological reality—they are involuntary responses that the subject simply cannot mask.
Potency and Pharmacokinetics: Clonazolam vs. 8-Aminoclonazolam
Clonazolam is a potent triazolobenzodiazepine that acts on GABA receptors. It is not approved for therapeutic use in the United States, yet its impact on human performance is profound.
• Potency: It is significantly more potent than its pharmaceutical cousin, clonazepam (Klonopin).
• The “Hangover” Effect: Impairment and sedation can persist for 24–30 hours following high-dose exposure. Even low doses () can result in lingering cognitive deficits the following day.
• The Metabolite: Emerging studies suggest that 8-aminoclonazolam may be even more potent than the parent drug, further complicating the window of impairment.
• Synergy: The risk of motor vehicle accidents is exacerbated when these substances are combined with alcohol or cannabis/THC products.
The Laboratory Challenge: “You Don’t Know What You Don’t Know”
The shift in drug trends over the last decade has rendered traditional “imprint identification” obsolete. To maintain forensic integrity, laboratories must adapt:
Chemical Testing Over Visual ID: With nearly 50% of Xanax and 80% of Oxycodone seized in the U.S. being counterfeit, labs can no longer rely on pill markings. Many counterfeits are sophisticated enough to fool even experienced chemists.
Global Surveillance: Monitoring trends in Australia, Russia, China, and the UK is essential to predict what will appear in local “smoke shops” or illicit markets.
Inter-Departmental Intelligence: Breaking down silos is critical. Open communication between drug chemistry, postmortem toxicology, and human performance teams allows for better method development and validation.
Strategic Insight: Testing both biological samples and recovered drug items in postmortem cases provides the “intel” needed to update screening libraries before these substances overwhelm human performance caseloads.
Conclusion
The NPS of today could be the mainstay of tomorrow. A decade ago, few would have predicted fentanyl would almost entirely displace heroin. Today, clonazolam is appearing in powders, blotter paper, and most frequently, counterfeit Xanax.
The latest NPS is the “gift” no one asked for, but as forensic professionals, we are the ones who have to open the package and deal with the contents.
Disclaimer: The opinions provided are my own and are not affiliated with any one entity that I consult for or provide guidance to.
